Clinical outcomes of newly diagnosed primary central nervous system lymphoma treated with zanubrutinib-based combination therapy

doi:10.5306/wjco.v14.i12.606

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2496)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-4) series.

Item

Count

PDF

WORD

HTML

1568

Figures (1-6)

114

Tables (1-4)

141

Sum=1870

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

113

Download

228

Sum=341

Publishing Process of This Article

Item

Count

Browse

Download

152

Sum=220

Dec 24, 2023 (publication date) through Aug 30, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Oncol. Dec 24, 2023; 14(12): 606-619
Published online Dec 24, 2023. doi: 10.5306/wjco.v14.i12.606

Table 3 Efficacy of high-dose methotrexate plus zanubrutinib for newly diagnosed primary central nervous system lymphoma

Parameter	N = 19
OS rate (%)	-
24-mo (95%CI)	94.1% (83.6%-100%)
Median PFS	-
24-mo (95%CI)	75.6% (53.4%-100%)
ORR (%)	84.2%
ASCT (consolidation therapy)	88.9%
Zanubrutinib (maintenance therapy)	80%
Median follow-up time (mo)	14.7
95%CI	3.9–30

OS: Overall survival; CI: Confidence interval; PFS: Progression-free survival; ORR: Objective response rate; ASCT: Autologous stem cell transplantation.

Citation: Wang N, Chen FL, Pan L, Teng Y, Wei XJ, Guo HG, Jiang XM, Huang L, Liu SC, Liang ZL, Li WY. Clinical outcomes of newly diagnosed primary central nervous system lymphoma treated with zanubrutinib-based combination therapy. World J Clin Oncol 2023; 14(12): 606-619
URL: https://www.wjgnet.com/2218-4333/full/v14/i12/606.htm
DOI: https://dx.doi.org/10.5306/wjco.v14.i12.606